New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eculizumab 300mg;  ;  ;   - solution for infusion - 300mg/30ml - active: eculizumab 300mg       excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - soliris® is indicated for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh)to reduce haemolysis.

European Union - English - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hemoglobinuria, paroxysmal - immunosuppressants - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1).

European Union - English - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinuria, paroxysmal - immunosuppressants - soliris is indicated in adults and children for the treatment of:paroxysmal nocturnal haemoglobinuria (pnh).evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). atypical haemolytic uremic syndrome (ahus).soliris is indicated in adults for the treatment of:refractory generalized myasthenia gravis (gmg) in patients who are anti-acetylcholine receptor (achr) antibody-positive (see section 5.1).neuromyelitis optica spectrum disorder (nmosd) in patients who are anti-aquaporin-4 (aqp4) antibody-positive with a relapsing course of the disease.

Canada - English - Health Canada

alexion pharma gmbh - eculizumab - solution - 10mg - eculizumab 10mg - complement inhibitors

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w-135 polysaccharide; neisseria meningitidis group y polysaccharide; tetanus toxoid carrier protein - injection, powder, for solution - 5 micrograms - neisseria meningitidis group a polysaccharide 5 micrograms; neisseria meningitidis group c polysaccharide 5 micrograms; neisseria meningitidis group w-135 polysaccharide 5 micrograms; neisseria meningitidis group y polysaccharide 5 micrograms; tetanus toxoid carrier protein ~44 micrograms

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - (mena lyo) meningococcal group a oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group c oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group w-135 oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group y oligosaccharide conjugated to crm197 protein - injection, powder, for solution - 10 microgram conjugated to 16.7-33.3 microgram - (mena lyo) meningococcal group a oligosaccharide conjugated to crm197 protein 10 microgram conjugated to 16.7-33.3 microgram; (mencwy) meningococcal group c oligosaccharide conjugated to crm197 protein 5 microgram conjudated to 7.1-12.5 microgram; (mencwy) meningococcal group w-135 oligosaccharide conjugated to crm197 protein 5 microgram conjugated to 3.3-8.3 microgram; (mencwy) meningococcal group y oligosaccharide conjugated to crm197 protein 5 microgram conjugated to 5.6-10 microgram

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid protein; meningococcal (serogroup a) polysaccharide (monovalent conjugate); meningococcal (serogroup c) polysaccharide (monovalent conjugate); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate); meningococcal (serogroup y) polysaccharide (monovalent conjugate) - injection, solution - 48 microgram (diptheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio) - diphtheria toxoid protein 48 mcg/dose (0.5 ml) (diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio); meningococcal (serogroup a) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup c) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup y) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml)

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - neisseria meningitidis c; tetanus toxoid - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - meningococcal vaccines - meningococcal vaccine - it is indicated for active immunisation in children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein - injection, suspension - neisseria meningitidis serogroup b recombinant lp2086 subfamily a protein 0.06 mg/0.5ml; neisseria meningitidis serogroup b recombinant lp2086 subfamily b protein 0.06 mg/0.5ml